Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
- Title
- Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Record Date
- 04/15/2021
- Vuga Group
- OBSERVATIONAL
- Change Status
- unchanged
- Recency Days
- 1,959.85
- Public Significance Score
- 0